Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Change in Receivables (2016 - 2025)

Amphastar Pharmaceuticals has reported Change in Receivables over the past 13 years, most recently at -$3.2 million for Q4 2025.

  • Quarterly results put Change in Receivables at -$3.2 million for Q4 2025, down 11.22% from a year ago — trailing twelve months through Dec 2025 was $6.4 million (down 70.62% YoY), and the annual figure for FY2025 was $6.4 million, down 70.62%.
  • Change in Receivables for Q4 2025 was -$3.2 million at Amphastar Pharmaceuticals, down from $13.8 million in the prior quarter.
  • Over the last five years, Change in Receivables for AMPH hit a ceiling of $23.2 million in Q1 2024 and a floor of -$12.3 million in Q2 2025.
  • Median Change in Receivables over the past 5 years was $4.3 million (2021), compared with a mean of $4.0 million.
  • Biggest five-year swings in Change in Receivables: surged 1430.46% in 2022 and later crashed 428.82% in 2024.
  • Amphastar Pharmaceuticals' Change in Receivables stood at $755000.0 in 2021, then surged by 1430.46% to $11.6 million in 2022, then crashed by 135.39% to -$4.1 million in 2023, then increased by 28.93% to -$2.9 million in 2024, then dropped by 11.22% to -$3.2 million in 2025.
  • The last three reported values for Change in Receivables were -$3.2 million (Q4 2025), $13.8 million (Q3 2025), and -$12.3 million (Q2 2025) per Business Quant data.